Co-Diagnostics

Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q4 2023

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SALT LAKE CITY, May 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be presenting at the H.C. Wainwright & Co. 2022 Global Investment Conference, being held in-person and virtually on May 23-26 in Miami, Florida.

Co-Diagnostics, Inc. to Participate in the H.C. Wainwright 2022 Global Investment Conference on May 23-26

Co-Diagnostics, Inc. (NASDAQ:CODX ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Andrew Benson - Head, IR Dwight Egan - Chairman, CEO & President Brian Brown - CFO & Company Secretary Conference Call Participants Yi Chen - H.C. Wainwright & Co. James Sidoti - Sidoti & Company Theodore O'Neill - Litchfield Hills Research Operator Good day, and welcome to the Co-Diagnostics Inc. First Quarter 2022 Earnings Results Conference Call.

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q1 2022 Results - Earnings Call Transcript

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 44.44% and 6.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q1 Earnings and Revenues Beat Estimates

Co-Diagnostics (NASDAQ:CODX) Inc has reported record 1Q revenue as the company says it plans to leverage its strong financial position to fund future growth initiatives. For the quarter ending March 31, 2022, the company reported revenue of $22.7 million, up from $20 million for the same quarter in 2021, which it attributed primarily to sales of its Logix Smart COVID-19 test.

Co-Diagnostics reports record 1Q revenue as company looks to expand into new markets and innovative molecular diagnostics solutions

Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 SALT LAKE CITY , May 12, 2022 /PRNewswire/ --  Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2022. Strong results highlighted by record first quarter revenue of $22.7 million and diluted EPS of $0.34 First-Quarter 2022 Financial Results: Revenue of $22.7 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $19.4 million, representing 85.5% of consolidated revenue Operating income of $9.8 million compared to $10.3 million a year ago, due to an increase in research and development expense Income before taxes of $13.1 million Net income of $11.7 million, compared to a net income of $7.9 million in the prior-year first quarter, representing $0.34 per fully diluted share Adjusted EBITDA of $11.4 million Cash, cash equivalents, and marketable securities totaled $97.4 million as of March 31, 2022, an increase of $7.5 million from December 31, 2021 "We are incredibly proud to deliver another solid quarter of growth following our record results in 2021," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.

Co-Diagnostics Reports Solid First Quarter 2022 Financial Results

SALT LAKE CITY , May 3, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the Medical Fair Brasil, held May 3-6, 2022, at the Expo Center Norte in São Paulo, Brazil. The international exhibition on hospital, diagnostic, pharmaceutical, medical and rehabilitation equipment and supplies is described on its website as a communication channel with the healthcare sector where companies present their products, innovations and services with the purpose of supplying and transforming the healthcare chain.

Co-Diagnostics, Inc. to Host Booth at Medical Fair Brasil 2022 in São Paulo on May 3-6

CoDiagnostics, Inc. (CODX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why the Earnings Surprise Streak Could Continue for CoDiagnostics, Inc. (CODX)

SALT LAKE CITY , April 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx,"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), held April 23-26, 2022, in Lisbon, Portugal. The congress, which brings together experts from clinical microbiology and infectious disease fields to present their latest findings, guidelines and experiences to an audience of over 14,000 colleagues, will also feature a hybrid format for the first time, to facilitate an onsite and online experience for attendees allowing for remote and face-to-face opportunities.

Co-Diagnostics, Inc. to Host Booth at ECCMID 2022 in Lisbon, Portugal on April 23-26

Co-Diagnostics (NASDAQ:CODX) has said that CoSara Diagnostics Pvt Ltd, its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (CDSCO) in India to manufacture and sell its SARAQ Hepatitis C (HCV) Viral Load Kit as an in vitro diagnostic (IVD). CoSara's new real-time HCV PCR test is built on the company's patented CoPrimer technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HCV, a disease with no effective vaccine that leads to nearly 300,000 deaths in 2019 according to the World Health Organization (WHO).

Co-Diagnostics says its CoSara Diagnostics Indian joint venture has received clearance to manufacture and sell its Hepatitis C Viral (HCV) Load Kit as an in vitro diagnostic

SALT LAKE CITY , April 19, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAQ™ Hepatitis C ("HCV") Viral Load Kit as an in vitro diagnostic ("IVD"). CoSara's new real-time HCV PCR test is built on the Company's patented CoPrimer™ technology and designed to be used as an aid in assessing response to antiviral treatments in patients diagnosed with HCV, a disease with no effective vaccine that leads to nearly 300,000 deaths in 2019 according to the World Health Organization ("WHO").

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Hepatitis C Viral Load Test

The company released its 2021 earnings, and investors weren't happy with them despite profitability guidance that beat estimates.

Why Co-Diagnostics Stock Tumbled by Nearly 12% Today

CoDiagnostics, Inc. (CODX) delivered earnings and revenue surprises of 66.67% and 5.11%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

CoDiagnostics, Inc. (CODX) Q4 Earnings Beat Estimates

Co-Diagnostics, Inc. (CODX) CEO Dwight Egan on Q4 2021 Results - Earnings Call Transcript

Co-Diagnostics (NASDAQ:CODX) Inc saw a healthy jump in year-over-year revenue driven by global sales of its Logix Smart COVID-19 tests, according to its latest financial results. The molecular diagnostics company clocked up $97.9 million in full-year 2021 revenue, an increase of $23.3 million over 2020 levels, and adjusted EBITDA of $52.1 million compared to $45.3 million in 2020.

Co-Diagnostics clocks up $97.9M in full year 2021 revenue on the strength of Logix Smart COVID-19 test sales

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher in Thursday's after-hours session after the company reported financial results and issued earnings guidance. Co-Diagnostics reported full year 2021 revenue of $97.89 million, which is up $23.3 million year-over-year.

Why Co-Diagnostics Stock Is Trading Higher After Hours

Achieved Record Full Year Revenue of $97.9 Million; Strength in Sales Momentum Provides Foundation to Achieve Solid FY'22 SALT LAKE CITY , March 24, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the full year ended December 31, 2021. • Revenue of $97.9 million, an increase of $23.3 million year-over-year • Adjusted EBITDA of $52.1 million in 2021 Full Year 2021 Financial Results: Revenue of $97.9 million, an increase of $23.3 million year-over-year, primarily due to sales of Logix Smart™ COVID-19 Tests throughout the world Gross profit increased to $86.3 million year-over-year, representing 88.2% of consolidated revenue Operating income improved to $46.1 million due to record revenue and gross profit for the year Income before taxes of $45.6 million Net income of $36.7 million, compared to a $42.5 million from the prior year, representing $1.23 per fully diluted share compared to $1.52 in 2020 Adjusted EBITDA of $52.1 million in 2021 improved from $45.3 million in 2020 Cash, cash equivalents, and marketable securities totaled $89.9 million at December 31, 2021, compared to $47.3 million as of December 31, 2020 Dwight Egan, Co-Diagnostics' Chief Executive Officer, said, "Our record performance during Fiscal 2021 reflects the strength of our innovative product portfolio, and our ability to quickly adapt and deliver our products to customers in regions experiencing increased demand.

Co-Diagnostics Reports Full Year 2021 Financial Results

SALT LAKE CITY , March 22, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will present at the 3rd Annual MarketsandMarkets Infectious Disease Diagnostics and Molecular Diagnostics Conference, held March 23-24, 2022, in London, England. Co-Diagnostics CEO Dwight Egan will be presenting on the Company's YourTest™ PCR at-home/point-of-care testing device to the international audience at 14:00 GMT on March 23rd.

Co-Diagnostics, Inc. to Present at MarketsandMarkets Conference on March 23-24 in London, England

Co-Diagnostics (NASDAQ:CODX) Inc has beefed up its Scientific Advisory Board with the addition of four new experts. The molecular diagnostics company is welcoming Idaho Technology/BioFire CSO Carl Wittwer, pathology professor Karen Carroll, biotech veteran Noriko Kusukawa and Yale research scientist Anne Wyllie to the board.

Co-Diagnostics adds four new experts to its Scientific Advisory Board

SALT LAKE CITY , March 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, is pleased to announce today that it has made several strategic additions to its Scientific Advisory Board ("SAB"). The Company welcomes Carl Wittwer, M.D.

Co-Diagnostics, Inc. Makes Strategic Additions to Scientific Advisory Board

CoDiagnostics, Inc. (CODX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

CoDiagnostics, Inc. (CODX) Surges 13.1%: Is This an Indication of Further Gains?

The diagnostics and research outfit gave investors a dose of good news today.

Why Co-Diagnostics Is Soaring Today

Co-Diagnostics Inc (NASDAQ: CODX) shares are trading higher Tuesday after the company announced its board authorized a share repurchase program, allowing Co-Diagnostics to repurchase up to $30 million of its common stock. "We believe that the current share price provides us.

Why Co-Diagnostics Shares Are Trading Higher Today

SALT LAKE CITY , March 15, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that its Board of Directors has authorized a share repurchase program that would allow the Company to repurchase up to $30 million of CODX common stock. "This share repurchase program is aligned with our commitment to return value to our shareholders and reflects confidence in our balance sheet and strong cash flow generation," remarked Brian Brown, Chief Financial Officer of Co-Diagnostics.

Co-Diagnostics, Inc. Announces Authorization of $30 Million Share Repurchase Program

SALT LAKE CITY , March 14, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2021 results on Thursday, March 24, 2022, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m.

CO-DIAGNOSTICS, INC. ANNOUNCES FOURTH QUARTER AND FULL YEAR 2021 EARNINGS RELEASE DATE AND WEBCAST

SALT LAKE CITY, Feb. 17, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be a premium sponsor of the upcoming Molecular Med Tri-Con held February 21-23, 2022 in San Diego, CA, which will also include a presentation by representatives of the Company and its newly-acquired subsidiary. Co-Diagnostics CEO Dwight Egan and Dr. Kirk Ririe, President of the Company's subsidiary, will be presenting in the conference's At-Home & Point-of-Care Diagnostics track on Monday, February 21 from 12:20 pm to 12:50 pm.

News for Co-Diagnostics Stock (CODX)